The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Primary Care–Based Models for the Treatment of Opioid Use Disorder: A Scoping Review
Open accessAbstract
Greater integration of medication-assisted treatment (MAT) for opioid use disorder (OUD) in U.S. primary care settings would expand access to treatment for this condition. Models for integrating MAT into primary care vary in structure. This article summarizes findings of a technical report for the Agency for Healthcare Research and Quality describing MAT models of care for OUD, based on a literature review and interviews with key informants in the field. The report describes 12 representative models of care for integrating MAT into primary care settings that could be considered for adaptation across diverse health care settings. Common components of existing care models include pharmacotherapy with buprenorphine or naltrexone, provider and community education, coordination and integration of OUD treatment with other medical and psychological needs, and psychosocial services and interventions. Models vary in how each component is implemented. Decisions about adopting MAT models of care should be individualized to address the unique milieu of each implementation setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209.pub2 · Cited by 1,654
The Changing Face of Heroin Use in the United States: A Retrospective Analysis of the Past 50 Years
Cicero, T. J., Ellis, M. S., Surratt, H. L., & Kurtz, S. P. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.366 · Cited by 1,168
Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure
Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Selby, P., Martin, P. R., & Fischer, G. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005359 · Cited by 986
D’Onofrio, G., O’Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., Bernstein, S. L., & Fiellin, D. A. (2015) · JAMA · doi:10.1001/jama.2015.3474 · Cited by 910
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Thompson, M. A., Mugavero, M. J., Amico, K. R., Cargill, V. A., Chang, L. W., Gross, R., Orrell, C., Altice, F. L., Bangsberg, D. R., Bartlett, J. G., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-11-201206050-00419 · Cited by 582
Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60358-9 · Cited by 555
Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone—Indiana, 2015
(2015) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2015.05.031 · Cited by 361
Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence
Fiellin, D. A., Pantalon, M. V., Chawarski, M. C., Moore, B. A., Sullivan, L. E., O'Connor, P. G., & Schottenfeld, R. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055255 · Cited by 351
Comer, S. D., Sullivan, M. A., Yu, E., Rothenberg, J. L., Kleber, H. D., Kampman, K., Dackis, C., & O’Brien, C. P. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.210 · Cited by 348
Buprenorphine Treatment for Hospitalized, Opioid-Dependent Patients: A Randomized Clinical Trial
Liebschutz, J. M., Crooks, D., Herman, D., Anderson, B., Tsui, J., Meshesha, L. Z., Dossabhoy, S., & Stein, M. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.2556 · Cited by 342
Jones, H. E., Johnson, R. E., Jasinski, D. R., O’Grady, K. E., Chisholm, C. A., Choo, R. E., Crocetti, M., Dudas, R., Harrow, C., Huestis, M. A., et al. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.11.013 · Cited by 295
Alford, D. P., LaBelle, C. T., Kretsch, N., Bergeron, A., Winter, M., Botticelli, M., & Samet, J. H. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.541 · Cited by 267
Komaromy, M., Duhigg, D., Metcalf, A., Carlson, C., Kalishman, S., Hayes, L., Burke, T., Thornton, K., & Arora, S. (2016) · Substance Abuse · doi:10.1080/08897077.2015.1129388 · Cited by 258
Altice, F. L., Bruce, R. D., Lucas, G. M., Lum, P. J., Korthuis, P. T., Flanigan, T. P., Cunningham, C. O., Sullivan, L. E., Vergara-Rodriguez, P., Fiellin, D. A., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318209751e · Cited by 256
Self-citationLaBelle, C. T., Han, S. C., Bergeron, A., & Samet, J. H. (2016) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.06.010 · Cited by 228
Long‐Term Treatment with Buprenorphine/Naloxone in Primary Care: Results at 2–5 Years
Fiellin, D. A., Moore, B. A., Sullivan, L. E., Becker, W. C., Pantalon, M. V., Chawarski, M. C., Barry, D. T., O'Connor, P. G., & Schottenfeld, R. S. (2008) · The American Journal on Addictions · doi:10.1080/10550490701860971 · Cited by 162
A Transitional Opioid Program to Engage Hospitalized Drug Users
Shanahan, C. W., Beers, D., Alford, D. P., Brigandi, E., & Samet, J. H. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1311-3 · Cited by 138
Lucas, G. M., Chaudhry, A. A., Hsu, J., Woodson, T., Lau, B. M., Olsen, Y. K., Keruly, J. C., Fiellin, D. A., Finkelstein, R., Barditch‐Crovo, P., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00003 · Cited by 119
Treating Homeless Opioid Dependent Patients with Buprenorphine in an Office-Based Setting
Alford, D. P., LaBelle, C. T., Richardson, J. M., O’Connell, J. J., Hohl, C., Cheng, D. M., & Samet, J. H. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-006-0023-1 · Cited by 105
Treatment of heroin dependence with buprenorphine in primary care
Fiellin, D. A., Pantalon, M. V., Pakes, J. P., O'Connor, P. G., Chawarski, M., & Schottenfeld, R. S. (2002) · The American Journal of Drug and Alcohol Abuse · doi:10.1081/ada-120002972 · Cited by 98
Fiellin, D. A., Weiss, L., Botsko, M., Egan, J. E., Altice, F. L., Bazerman, L. B., Chaudhry, A. A., Cunningham, C. O., Gourevitch, M. N., Lum, P. J., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182097537 · Cited by 87
Lum, P. J., Little, S., Botsko, M., Hersh, D., Thawley, R., Egan, J. E., Mitty, J. A., Boverman, J. F., & Fiellin, D. A. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31820a9a82 · Cited by 77
Weiss, L., Netherland, J. C., Egan, J. E., Flanigan, T., Fiellin, D. A., Finkelstein, R., & Altice, F. L. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31820a8226 · Cited by 77
Patients' Reasons for Choosing Office-Based Buprenorphine: Preference for Patient-Centered Care
Korthuis, P. T., Gregg, J. L., Rogers, W. E., McCarty, D. W., Nicolaidis, C., & Boverman, J. F. (2010) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3181cc9610 · Cited by 71
Self-citationA Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
Sullivan, L. E., Barry, D. T., Moore, B. A., Chawarski, M. C., Tetrault, J. M., Pantalon, M. V., O’Connor, P. G., Schottenfeld, R. S., & Fiellin, D. A. (2006) · Clinical Infectious Diseases · doi:10.1086/508182 · Cited by 68
Korthuis, P. T., Tozzi, M. J., Nandi, V., Fiellin, D. A., Weiss, L., Egan, J. E., Botsko, M., Acosta, A., Gourevitch, M. N., Hersh, D., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318209754c · Cited by 66
Self-citationOregon’s Medicaid Coordinated Care Organizations
McConnell, K. J. (2016) · JAMA · doi:10.1001/jama.2016.0206 · Cited by 60
Korthuis, P. T., Fiellin, D. A., Fu, R. F., Lum, P. J., Altice, F. L., Sohler, N., Tozzi, M. J., Asch, S. M., Botsko, M., Fishl, M., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31820bc9a5 · Cited by 52
Self-citationCarrieri, P., Rey, D., Loundou, A., Lepeu, G., Sobel, A. T., & Obadia, Y. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00189-3 · Cited by 48
Weiss, L., Egan, J. E., Botsko, M., Netherland, J. C., Fiellin, D. A., & Finkelstein, R. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182097426 · Cited by 46
Patient Perspectives on Buprenorphine/Naloxone Treatment in the Context of HIV Care
Egan, J. E., Netherland, J. C., Gass, J. D., Finkelstein, R., & Weiss, L. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182097561 · Cited by 40
Chaudhry, A. A., Botsko, M., Weiss, L., Egan, J. E., Mitty, J. A., Estrada, B. D., Lucas, G. M., Woodson, T., Flanigan, T., & Fiellin, D. A. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318209d3b9 · Cited by 37
The Science and Practice of Medication-Assisted Treatments for Opioid Dependence
Pecoraro, A., Ma, M., & WOODY, G. E. (2012) · Substance Use & Misuse · doi:10.3109/10826084.2012.663292 · Cited by 30
The Impact of Cocaine Use on Outcomes in HIV-Infected Patients Receiving Buprenorphine/Naloxone
Sullivan, L. E., Botsko, M., Cunningham, C. O., O’Connor, P. G., Hersh, D., Mitty, J. A., Lum, P. J., Schottenfeld, R. S., & Fiellin, D. A. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182097576 · Cited by 30
Cheever, L. W., Kresina, T. F., Cajina, A., & Lubran, R. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318209740f · Cited by 30
Schackman, B. R., Leff, J. A., Botsko, M., Fiellin, D. A., Altice, F. L., Korthuis, P. T., Sohler, N., Weiss, L., Egan, J. E., Netherland, J. C., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31820a9a66 · Cited by 20
Self-citationPolicy Implications of Integrating Buprenorphine/Naloxone Treatment and HIV Care
Finkelstein, R., Netherland, J. C., Sylla, L. N., Gourevitch, M. N., Cajina, A., & Cheever, L. W. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31820a9a97 · Cited by 19
Stoller, K. B. (2015) · Addiction Science & Clinical Practice · doi:10.1186/1940-0640-10-s1-a63 · Cited by 16
Cited by
Volkow, N. D., & Blanco, C. (2023) · World psychiatry · doi:10.1002/wps.21073 · Cited by 503
Understanding Links among Opioid Use, Overdose, and Suicide
Bohnert, A. S. B., & Ilgen, M. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1802148 · Cited by 317
Use and misuse of opioids in chronic pain
Volkow, N., Benveniste, H., & McLellan, A. T. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-011817-044739 · Cited by 279
Causes of Death After Nonfatal Opioid Overdose
Olfson, M., Crystal, S., Wall, M., Wang, S., Liu, S.-M., & Blanco, C. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.1471 · Cited by 121
Reif, S., Brolin, M. F., Stewart, M. T., Fuchs, T. J., Speaker, E., & Mazel, S. B. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.07.007 · Cited by 58
Metadata
- Authors
- Korthuis, P. T., McCarty, D., Weimer, M., Bougatsos, C., Blazina, I., Zakher, B., Grusing, S., Devine, B., & Chou, R.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2017-02-21
- Volume
- 166
- Issue
- 4
- Pages
- 268-278
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2560789041
- Cited by
- 297
- References
- 41
- FWCI
- 20.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.